

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
 Stylesheet Version v1.2

EPAS ID: PAT5308779

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT
CONVEYING PARTY DATA	
Name	Execution Date
HAOYANG YU	12/28/2018
ZHONG WANG	12/28/2018
ZHENGCHENG LI	12/28/2018
RECEIVING PARTY DATA	
Name:	BENHEALTH BIOPHARMACEUTIC (SHENZHEN) CO. LTD.
Street Address:	BUILDING A9-2F, TIANLIAO INDUSTRIAL PARK A, TAOYUAN STREET, NANSHAN DISTRICT
City:	SHENZHEN
State/Country:	CHINA
Postal Code:	518055
PROPERTY NUMBERS Total: 1	
Property Type	Number
Application Number:	16312100
CORRESPONDENCE DATA	
Fax Number:	(202)585-0046
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
Phone:	404-815-6500
Email:	nito@kilpatricktownsend.com
Correspondent Name:	KILPATRICK TOWNSEND & STOCKTON LLP
Address Line 1:	1100 PEACHTREE STREET
Address Line 2:	SUITE 2800
Address Line 4:	ATLANTA, GEORGIA 30309
ATTORNEY DOCKET NUMBER:	073618-1119183
NAME OF SUBMITTER:	NANA ITO
SIGNATURE:	/Nana Ito/
DATE SIGNED:	01/04/2019
Total Attachments: 3	
source=1119183_Assignment#page1.tif	
source=1119183_Assignment#page2.tif	

ASSIGNMENT
(Patent Application)

We, the undersigned, have invented certain inventions and improvements disclosed in a utility patent application entitled

“BISPECIFIC ANTIBODY AND ANTIBODY CONJUGATE FOR TUMOUR THERAPY AND USE THEREOF,”

filed with the U.S. Patent & Trademark Office on December 20, 2018

and assigned Patent Application No. 16/312,100

which is a U.S. national phase application under 35 U.S.C. 371 of PCT/CN2017/089307 filed on June 21, 2017, and claims priority to Chinese patent application Nos. 201610456791.8 filed on June 22, 2016 and 201710052692.8 filed January 24, 2017.


For one dollar (\$1.00) and other good and valuable consideration, the receipt and sufficiency of which we acknowledge, we:

1. Agree to assign, transfer, convey, and sell, hereby assign, transfer, convey, and sell and have assigned, transferred, conveyed, and sold to BENHEALTH BIOPHARMACEUTIC (SHENZHEN) CO. LTD., a corporation of China, having a principal place of business at Building A9-2F, Tianliao Industrial Park Taoyuan Street, Nanshan District Shenzhen, Guangdong 518055, CHINA (“Assignee”), the entire right, title, and interest in and to:
 - (a) all intellectual property (including, without limitation, any innovation, information, invention, discovery, product, process, work or design) disclosed, embodied, shown, or claimed in the above-referenced patent application, implicitly or explicitly;
 - (b) the above-referenced patent application, and all applications based in whole or in part upon the above-referenced patent application, including, without limitation, all applications that are a provisional, non-provisional, design, divisional, continuation, continuation-in-part, registration, utility model, industrial design, reissue, renewal, substitute, extension, reexamination, post-grant review, inter partes review, supplemental examination or non-U.S. patent application or application for other rights based in whole or in part on the above-referenced patent application;
 - (c) the right to claim priority to the above-referenced patent application, and any and all applications referenced in subsection (b); and

- (d) all patents (including, without limitation, all U.S. and non-U.S. patents, registrations, utility models, industrial designs, design patents, counterparts, continuations, continuations-in-part, divisionals, reissues, renewals, substitutes, extensions, reexaminations, post-grant reviews, inter partes reviews and supplemental examinations) that are granted or issued upon, or that claim priority to, any and all applications described in (b) of this paragraph or that disclose or claim intellectual property described in (a) of this paragraph, in whole or in part; and
 - (e) all claims for damages by reason of past infringement of any rights under the applications or patents described in (a), (b) or (c) of this paragraph (including provisional rights to reasonable royalties pursuant to 35 U.S.C. §154(d)) and the right to sue for and collect such damages and royalties for Assignee's own use.
2. Authorize and request the U.S. Patent and Trademark Office or any other U.S. or non-U.S. agency to issue to the Assignee any and all patent(s), or other rights or documents, resulting from the intellectual property, patent application(s) and patents described in paragraph 1 of this Assignment.
 3. Agree to sign all papers and documents, including without limitation, applications, declarations, oaths and petitions, and, at the Assignee's expense, perform any other acts that are necessary in connection with prosecution of patent application(s) or intellectual property described in paragraph 1 of this Assignment and the enforcement of patent(s) or other rights resulting from such patent application(s) or intellectual property.
 4. Agree that the terms, covenants, and conditions of this Assignment shall inure to the benefit of the Assignee, its successors, assigns and other legal representative, and shall be binding upon us, as well as our heirs, legal representatives, and assigns.
 5. Promise and affirm that we have not entered, and will not enter, into any assignment, contract, or understanding that conflicts with this Assignment.
 6. Authorize Kilpatrick Townsend & Stockton to insert above the application number and filing date of the above-described patent application when known.

Signed on the dates indicated beside our signatures.

Date: 28. Dec. 2018


Haoyang YU

WITNESSED BY:


Name: Ji Zhang

Date: 28. Dec. 2018.

Name: Guifeng Liang

Date: 28 Dec. 2018.

Date: 2018.12.28


Zhong WANG

WITNESSED BY:


Name: Ji Zhang

Date: 28. Dec. 2018.

Name: Guifeng Liang

Date: 28 Dec. 2018

Date: 28. Dec. 2018


Zhengcheng LI

WITNESSED BY:

Name: Ji Zhang

Date: 28. Dec. 2018.

Name: Guifeng Liang

Date: 28 Dec 2018